Traws Pharma, Inc. — Director's Dealing 2016

Aug 18, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2016-07-29

Reporting Person: TYNDALL CAPITAL PARTNERS L P (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	520832	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants (right to buy)	$4.92	2021-07-27	Common Stock (390624)		Indirect

Footnotes

F1: The 520,832 shares of common stock, par value $0.01 per share (the "Shares"), and the warrants to purchase up to 390,624 Shares reported herein are held by Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"). Tyndall Capital Partners, L.P. is the general partner of Tyndall, and possesses the sole power to vote and the sole power to direct the disposition of all Shares held by Tyndall. The reporting person's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.